Business Wire

CALLALY

20.11.2020 12:38:09 CET | Business Wire | Press release

Share
Period-care B-corp Callaly’s Tampliner Named to Time’s List of the 100 Best Inventions of 2020

The Tampliner, the period-care innovation created by UK-based B-corp Callaly , has been recognised in TIME’s 100 Best Inventions of 2020 - its annual list of the 100 Best Inventions that are making the world better, smarter and even a bit more fun. Callaly is one of only eight British companies to make this year’s list.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005371/en/

Callaly set out to improve the $34bn period care industry with the launch of the Tampliner, a completely new period care product and first design upgrade to the tampon in 90 years. It is a 2-in-1 period product that combines an organic cotton tampon with a soft mini-liner for extra protection against leaks, connected by a ‘virtual applicator’.

The Tampliner, which is designed and manufactured in the UK and was launched in February 2020, was invented by Dr Alex Hooi, a senior British gynaecologist and Fellow of the Royal College of Obstetricians and Gynaecologists and developed by garment technologist Ewa Radziwon, who trained at London College of Fashion.

The British manufactured product is protected by four granted patent families covering 80% of the global market. It is now being exported across Europe in Sweden, the Netherlands and Ireland, and has been trialled with positive results in China.

Callaly, which has raised £13.2m through private investment and government funding, is backed by Innovate UK, having received five tranches totalling £3.9m to support the development and manufacture of the Tampliner. The company employs 20 people in its London HQ.

Callaly’s founder and CEO, Thang Vo-Ta said: “Our whole team is honoured that the Tampliner has been recognised by TIME as a pioneering invention. The period-care industry has been failing people for decades. Little to no R&D in the space means that many people with periods are compromising their health, comfort and convenience, with no choice but to put up with the dissatisfaction they feel. With our 2-in-1 invention we set out to address these problems from every angle and truly make people’s lives better. The Tampliner paves the way for further product innovations to radically improve people’s experiences of periods across the globe.”

Dr Ian Campbell, Executive Chair (Interim) Innovate UK said: "Innovate UK has been proud to support Callaly’s journey over the years, from innovation to manufacturing and now global expansion. This recognition from TIME acknowledges the great potential of R&D-backed British businesses like Callaly to change the world for the better."

Image of the tampliner can be found here .

See the full list here: www.time.com/best-inventions-2020

See the international cover of TIME featuring the 100 Best Inventions of 2020 here: bit.ly/3lJM8ss

ENDS

About Callaly:
British based Callaly is a certified B Corp- a for-profit company that’s committed to using business as a force for good. There are over 3,500 certified B Corps in the world including Danone N. America and Unilever’s Ben & Jerry. Every decision Callaly makes, no matter how small, is taken with an eye on the wider global impact. Callaly donates at least 1% of sales to charities supporting women & children.

Callaly offers a range of high quality period care products managed through its ISO9001 based Quality Management System including award-winning Tampliners, pantyliners, day pads, night pads and tampons- all in a range of different absorbencies. All the products are made with 100% organic cotton and are free from dioxins, perfumes, and pesticides. The Earth-friendly products are all wrapped in sustainable packaging.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 21:30:00 CET | Press release

Obtains Interim Approval to Access $125 Million of DIP FinancingGlobal Operations and Services to Customers Continue in Normal Course Without Interruption During Restructuring Process; All Trade Vendors and Suppliers to be Paid in Full Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye